Company profile
GlycoEra AG
GlycoEra AG is a biotechnology company building a high-value pipeline of medicines based on deep expertise in glycobiology and protein degradation. GlycoEras innovative CustomGlycan platform enables the design, engineering, and development of novel biologics for a broad range of indications. GlycoEra is advancing a range of assets toward human clinical studies.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2024
Top 100 Swiss Startup Award 2023
Top 100 Swiss Startup Award 2022
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
